The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology
Open accessAbstract
OBJECTIVE: To update the 2005 American Academy of Neurology (AAN) guideline on corticosteroid treatment of Duchenne muscular dystrophy (DMD). METHODS: We systematically reviewed the literature from January 2004 to July 2014 using the AAN classification scheme for therapeutic articles and predicated recommendations on the strength of the evidence. RESULTS: Thirty-four studies met inclusion criteria. RECOMMENDATIONS: In children with DMD, prednisone should be offered for improving strength (Level B) and pulmonary function (Level B). Prednisone may be offered for improving timed motor function (Level C), reducing the need for scoliosis surgery (Level C), and delaying cardiomyopathy onset by 18 years of age (Level C). Deflazacort may be offered for improving strength and timed motor function and delaying age at loss of ambulation by 1.4-2.5 years (Level C). Deflazacort may be offered for improving pulmonary function, reducing the need for scoliosis surgery, delaying cardiomyopathy onset, and increasing survival at 5-15 years of follow-up (Level C for each). Deflazacort and prednisone may be equivalent in improving motor function (Level C). Prednisone may be associated with greater weight gain in the first years of treatment than deflazacort (Level C). Deflazacort may be associated with a greater risk of cataracts than prednisone (Level C). The preferred dosing regimen of prednisone is 0.75 mg/kg/d (Level B). Over 12 months, prednisone 10 mg/kg/weekend is equally effective (Level B), with no long-term data available. Prednisone 0.75 mg/kg/d is associated with significant risk of weight gain, hirsutism, and cushingoid appearance (Level B).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Randomized, Double-Blind Six-Month Trial of Prednisone in Duchenne's Muscular Dystrophy
Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Fenichel, G. M., Miller, J. P., King, W., Signore, L., Pandya, S., Florence, J., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198906153202405 · Cited by 520
Self-citationBiggar, W. D., Harris, V. A., Eliasoph, L., & Alman, B. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.01.010 · Cited by 371
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., & Kissel, J. T. (2007) · Neurology · doi:10.1212/01.wnl.0000260974.41514.83 · Cited by 283
Griggs, R. C. (1991) · Archives of Neurology · doi:10.1001/archneur.1991.00530160047012 · Cited by 279
Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy
Fenichel, G. M., Florence, J. M., Pestronk, A., Mendell, J. R., Moxley, R. T., Griggs, R. C., Brooke, M. H., Miller, J. P., Robison, J., King, W., et al. (1991) · Neurology · doi:10.1212/wnl.41.12.1874 · Cited by 263
Self-citationRicotti, V., Ridout, D. A., Scott, E., Quinlivan, R., Robb, S. A., Manzur, A. Y., Muntoni, F., on behalf of the NorthStar Clinical Network, Manzur, A., Muntoni, F., et al. (2013) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303902 · Cited by 263
Bonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., Lanzi, G., & Angelini, C. (2000) · Muscle & Nerve · doi:10.1002/1097-4598(200009)23:9<1344::aid-mus4>3.0.co;2-f · Cited by 231
Deflazacort treatment of Duchenne muscular dystrophy
Biggar, W. D., Gingras, M., Fehlings, D. L., Harris, V. A., & Steele, C. A. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.109601 · Cited by 214
Schram, G., Fournier, A., Leduc, H., Dahdah, N., Therien, J., Vanasse, M., & Khairy, P. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.12.008 · Cited by 213
Cited by
Birnkrant, D. J., Bushby, K., Bann, C. M., Apkon, S. D., Blackwell, A., Brumbaugh, D., Case, L. E., Clemens, P. R., Hadjiyannakis, S., Pandya, S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30024-3 · Cited by 1,370
Birnkrant, D. J., Bushby, K., Bann, C. M., Alman, B. A., Apkon, S. D., Blackwell, A., Case, L. E., Cripe, L., Hadjiyannakis, S., Olson, A. K., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30025-5 · Cited by 1,167
Corticosteroids for the treatment of Duchenne muscular dystrophy
Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., & Manzur, A. Y. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003725.pub4 · Cited by 493
Liu, G., Lipari, P., Mollin, A., Jung, S., Teplova, I., Li, W., Ying, L., More, V., Lennox, W., Yeh, S., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddad173 · Cited by 23
Metadata
- Authors
- Gloss, D., Moxley, R. T., Ashwal, S., & Oskoui, M.
- Venue
- Neurology
- Published
- 2016-02-02
- Volume
- 86
- Issue
- 5
- Pages
- 465-472
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2306713582
- Cited by
- 258
- References
- 33
- FWCI
- 12.34
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. https://app.cochat.ai/papers/10.1212/wnl.0000000000002337
- The paper
- Gloss, D., Moxley, R. T., Ashwal, S., & Oskoui, M. (2016). Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. https://doi.org/10.1212/wnl.0000000000002337
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.